2 results
Approved WMOCompleted
To evaluate whether the e-mental health intervention E-PsEYE is cost-effective in comparison with usual care from a healthcare and societal perspective in reducing depression and anxiety in patients with retinal exudative diseases. In addition, a…
Approved WMOPending
The objectives of this are to establish the safety, tolerability, and preliminary efficacy of VRDN-001, and the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of VRDN-001 in NHV and TED patients over a dose range of 3.0 to 20.0 mg/kg.